Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Francesca PalandriDaniela BartolettiAlessandra IurloMassimiliano BonifacioElisabetta AbruzzeseGiovanni CaocciElena M ElliGiuseppe AuteriMario TiribelliNicola PolverelliMaurizio MiglinoFlorian H HeidelAlessia TieghiGiulia BenevoloEloise BeggiatoCarmen FavaFrancesco CavazziniNovella PuglieseGianni BinottoCostanza BosiBruno MartinoMonica CrugnolaEmanuela OttavianiGiorgia MicucciMalgorzata M TrawinskaAntonio CuneoMonica BocchiaMauro KramperaFabrizio PaneRoberto M LemoliDaniela CilloniNicola VianelliMichele CavoGiuseppe A PalumboMassimo BrecciaPublished in: Cancer (2022)
Personalized approaches beyond RUX monotherapy may be useful in PB-4 and particularly in PB-9 patients.